We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    LDX0419
Previous Study | Return to List | Next Study

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04899271
Recruitment Status : Active, not recruiting
First Posted : May 24, 2021
Last Update Posted : May 3, 2022
Sponsor:
Information provided by (Responsible Party):
Dompé Farmaceutici S.p.A

Tracking Information
First Submitted Date  ICMJE May 10, 2021
First Posted Date  ICMJE May 24, 2021
Last Update Posted Date May 3, 2022
Actual Study Start Date  ICMJE December 14, 2020
Estimated Primary Completion Date June 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 21, 2021)
Proportion of patients with HbA1c <7% and daily insulin requirement <0.50 IU/Kg/day [ Time Frame: Month 12 ]
The sample size of the study is calculated on the "proportion of patients with a HbA1c < 7% and daily insulin requirement <0.50 IU/Kg/day", a post-hoc composite endpoint derived from data of the phase 2 trial (MEX0114), considering a larger effect size expected from the longer treatment length (one year versus 3 months). The time frame for the primary endpoint has been set at Month 12 (Week 52) in order to evaluate the potential of ladarixin effects on a long-term projection.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 21, 2021)
  • Proportion of patients with HbA1c < 7% and daily insulin requirement <0.50 IU/Kg/day [ Time Frame: Months 6 and 18 ]
    The sample size of the study is calculated on the "proportion of patients with a HbA1c < 7% and daily insulin requirement <0.50 IU/Kg/day", a post-hoc composite endpoint derived from data of the phase 2 trial (MEX0114), considering a larger effect size expected from the longer treatment length (one year versus 3 months). Follow-up is extended up to 18 months to evaluate the potential persistency of any glycemic benefit.
  • Proportion of patients with a reduction in HbA1c% > 0.5% from baseline and daily insulin requirement <0.50 IU/Kg [ Time Frame: Months 6, 12 and 18 ]
    Proportion of patients with a reduction in HbA1c% > 0.5% from baseline and daily insulin requirement <0.50 IU/Kg/day was calculated
  • 2-hour AUC of C-peptide response to the MMTT [ Time Frame: Months 6, 12 and 18 ]
    C-peptide level is a widely used measure of pancreatic beta-cell function. The MMTT is one of the methods for its estimation. The MMTT was performed after an overnight fast, at baseline (within 1 week prior to randomization), and at each follow-up visit on weeks 13±1, 26±2, and 52±2. Prior to the test, patients withheld long-acting insulin on the morning of the test. Rapid-acting and short-acting insulin were allowed up to 6hrs and 2 hrs, respectively, before the test. The test was rescheduled if the patient had a capillary glucose value of >200mg/dL or <70mg/dL. After 2 pre-meal basal samples had been drawn between -20 to 0 min (basal 1 and basal 2), patients were given 6mL/kg of a high protein nutritional drink up to a maximum of 360mL, to be drunk within 5 min. Post-meal samples were drawn at 15, 30, 60, 90, 120 min after the meal at Months 6, 12 and 18.
  • Time in range (TIR) by Continuous Glucose Monitoring (CGM) [ Time Frame: Months 6, 12 and 18 ]
    Continuous glucose monitors (CGM) continually monitors glucose plasma levels through an external device that's attached to the body, and gives real-time updates.Time in range is the amount of time the patient spends in the target blood sugar (blood glucose) range-between 70 and 180 mg/dL for most people. The time in range method works with the individual CGM's data by looking at the amount of time blood sugar has been in target range and the times it has been high (hyperglycemia) or low (hypoglycemia). This data is helpful in finding out which types of foods and what activity level causes patient's blood sugar to rise and fall.
  • HbA1c levels [ Time Frame: Months 6, 12 and 18 ]
    HbA1c measurement can be used as a diagnostic test for diabetes providing that stringent quality assurance tests are in place and assays are standardised to criteria aligned to the international reference values, and there are no conditions present which preclude its accurate measurement. An HbA1c of 6.5% is recommended as the cut point for diagnosing diabetes. A value of less than 6.5% does not exclude diabetes diagnosed using glucose tests.
  • Proportion of patients with HbA1c < 7% who did not experience severe hypoglycemic events during treatment [ Time Frame: Months 6, 12 and 18 ]
    For the purpose of this study, a severe hypoglycaemic event is defined as an event with one of the following symptoms: memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness or visual symptoms, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level <54mg/dL (3.0 mmol/L) or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.
  • Additional Glucose Variability Indices derived from CGM: PPG [ Time Frame: Months 6, 12 and 18 ]
    PPG=2-hour postprandial glucose. All these glycemic variability indices refer to the intra-day or inter-day values and differences derived from the glucose values (these latter expressed in mg/dL) collected index by index using continuous glucose monitoring (CGM) System
  • Additional Glucose Variability Indices derived from CGM: MAGE [ Time Frame: Months 6, 12 and 18 ]
    MAGE=Mean Amplitude Glycemic Excursions. All these glycemic variability indices refer to the intra-day or inter-day values and differences derived from the glucose values (these latter expressed in mg/dL) collected index by index using continuous glucose monitoring (CGM) System.
  • Additional Glucose Variability Indices derived from CGM: CONGA-n [ Time Frame: Months 6, 12 and 18 ]
    CONGA-n=continuous overall net glycemic action. All these glycemic variability indices refer to the intra-day or inter-day values and differences derived from the glucose values (these latter expressed in mg/dL) collected index by index using continuous glucose monitoring (CGM) System.
  • Additional Glucose Variability Indices derived from CGM: MODD [ Time Frame: Months 6, 12 and 18 ]
    MODD=Mean Of the Daily Differences. All these glycemic variability indices refer to the intra-day or inter-day values and differences derived from the glucose values (these latter expressed in mg/dL) collected index by index using continuous glucose monitoring (CGM) System.
  • Additional Glucose Variability Indices derived from CGM: mean daily blood glucose [ Time Frame: Months 6, 12 and 18 ]
    All these glycemic variability indices refer to the intra-day or inter-day values and differences derived from the glucose values (these latter expressed in mg/dL) collected index by index using continuous glucose monitoring (CGM) System.
  • Additional Glucose Variability Indices derived from CGM: Standard Deviation (SD) [ Time Frame: Months 6, 12 and 18 ]
    All these glycemic variability indices refer to the intra-day or inter-day values and differences derived from the glucose values (these latter expressed in mg/dL) collected index by index using continuous glucose monitoring (CGM) System.
  • Number of self-reported episodes of severe hypoglycemia [ Time Frame: Months 6, 12 and 18 ]
    For the purpose of this study, a severe hypoglycaemic event is defined as an event with one of the following symptoms: memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness or visual symptoms, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level <54mg/dL (3.0 mmol/L) or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.
  • Average (previous 3 days) daily insulin requirements (IU/kg/day) [ Time Frame: Months 6, 12 and 18 ]
    For the purpose of this study, daily insulin is averaged over the previous 3 days.Insulin requirement (IU/kg/day averaged over the previous 3 days) was to be recorded to Months 6, 12 and 18. Patients were admitted to intensive diabetes management, according to current ADA recommendation [2014]. Patients were instructed to self-monitor their glucose values at least 4 times a day and to report (glucose meter/log) outcome to the diabetes management team. Insulin intake was adjusted to target HbA1c levels of less than 7% and self-monitored (fingerstick):
    • pre-prandial blood glucose of 70-130 mg/dL
    • post-prandial blood glucose < 180 mg/dL
    • bed-time blood glucose of 110-150 mg/dL
  • Estimated Glucose Disposal Rate (eGDR) [ Time Frame: Months 6, 12 and 18 ]
    Estimated Glucose Disposal Rate (eGDR) is a marker for the Assessment of Insulin Resistance and a validated clinical tool for estimating insulin sensitivity in type 1 diabetes.
  • Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Throughout the study up to 18 months ]
    An AE is any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the trial intervention. A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
Official Title  ICMJE A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes and Preserved Beta-cell Function at Baseline.
Brief Summary

The objectives of this clinical trial are:

  • to evaluate whether a 12 month treatment with ladarixin is effective to improve glycemic control in newly diagnosed T1D adult patients with preserved beta-cell function.
  • to evaluate the safety of ladarixin in the specific clinical setting
Detailed Description

The study is a phase 2, multicenter, double-blind, placebo-controlled study. It will randomize approximately 75 adult patients with new-onset type 1 diabetes (T1D) and preserved beta-cell function (fasting C-peptide >0.205 nmol/l) at baseline. Patients will be assigned (2:1) to receive either oral ladarixin treatment (400 mg b.i.d. for 13 cycles of 14 days on/14 days off - treatment group) or placebo (control group).

Recruitment will be competitive among the study sites, until the planned number of patients is randomized.

Ladarixin and placebo will be both administered for 1 year. All patients will be followed-up for 18 months from the 1st administration of the study medication. The study database will be locked and data analyzed when the last patient randomized has completed month 12 follow-up visit. After this time point, the follow-up will continue under open-label conditions up to month 18,

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Appearance, including packaging and labelling, of the IMP (capsules, packaging) will not allow to recognize actual treatment (either ladarixin or placebo).
Primary Purpose: Treatment
Condition  ICMJE New-onset Type 1 Diabetes
Intervention  ICMJE
  • Drug: Ladarixin
    400 mg b.i.d. for 13 cycles of 14 days on/14 days off
    Other Name: LDX
  • Other: Placebo
    Placebo will be administered orally with the same scheme of administration of LDX to preserve blinding
Study Arms  ICMJE
  • Experimental: Ladarixin
    The treatment group will receive 400 mg b.i.d. for 13 cycles of 14 days on/14 days off)
    Intervention: Drug: Ladarixin
  • Placebo Comparator: Placebo
    The control group will receive matched placebo
    Intervention: Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: May 2, 2022)
25
Original Estimated Enrollment  ICMJE
 (submitted: May 21, 2021)
75
Estimated Study Completion Date  ICMJE December 2023
Estimated Primary Completion Date June 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male and female patients aged 18-45 years, inclusive;
  2. New-onset T1D (1st IMP dose within 100 days from 1st insulin administration);
  3. Positive for at least one diabetes-related auto-antibody (anti-GAD; IAA, if obtained within 10 days of the onset of insulin therapy; IA-2 antibody; ZnT8);
  4. Require, or has required at some time, insulin therapy through multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII);
  5. Fasting C peptide ≥0.205nmol/L on two occasions;
  6. Patient able to comply with all protocol procedures for the duration of the study, including scheduled follow-up visits and examinations;
  7. Patients who have given written informed consent prior of any study-related procedure not part of standard medical care.

Exclusion Criteria:

  1. Any other chronic disease, including type 2 diabetes, apart from autoimmune hypothyroidism requiring thyroid hormone replacement only; patients with severe (myxedema) disease potentially requiring immunosuppressive therapy will be excluded;
  2. Moderate to severe renal impairment as per estimated Glomerular Filtration Rate (eGFR) 60 mL/min/1.73 m2, as determined using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation (see Appendix 14.4.3);
  3. Hepatic dysfunction defined by increased ALT/AST > 3 x upper limit of normal (ULN) and increased total bilirubin > 3 mg/dL [>51.3 μmol/L];
  4. Hypoalbuminemia defined as serum albumin < 3 g/dL;
  5. QTcF > 470 msec;
  6. A history of significant cardiovascular disease/abnormality
  7. Occurrence of an episode of ketoacidosis or hypoglycemic coma in the past 2 weeks;
  8. Known hypersensitivity to non-steroidal anti-inflammatory drugs;
  9. Concomitant treatment with drugs metabolized by CYP2C9 with a narrow therapeutic index [i.e., phenytoin, warfarin, sulphanylurea hypoglycemics (e.g. tolbutamide, glipizide, glibenclamide/glyburide, glimepiride, nateglinide) and high dose of amitriptyline (>50 mg/day)];
  10. Previous (within 2 weeks prior to randomization) and concomitant treatment with antidiabetic agents as metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors, SGLT2-inhibitors or amylin, or any medications known to influence glucose tolerance (e.g. beta-blockers, angiotensin-converting enzyme inhibitors, interferons, quinidine antimalarial drugs, lithium, niacin, etc.);
  11. Past (within 1 month prior to randomization) or current administration of any immunosuppressive medications (including oral, inhaled or systemically injected steroids) and use of any investigational agents, including any agents that impact the immune response or the cytokine system;
  12. Significant systemic infection during the 4 weeks before the first dose of the study drug (e.g., infection requiring hospitalization, major surgery, or IV antibiotics to resolve; other infections, e.g., bronchitis, sinusitis, localized cellulitis, candidiasis, or urinary tract infections, must be assessed on a case-by-case basis by the investigator regarding whether they are serious enough to warrant exclusion);
  13. Hepatitis A (IgM), hepatitis B (not due to immunization), hepatitis C and HIV positive serologic status Serologic evidence of current infectious liver disease (hepatitis A, B, or C), including ant hepatitis A virus (immunoglobulin M), hepatitis B surface antigen, or ant hepatitis C virus and HIV;
  14. Pregnant or breast feeding women. Unwillingness to use effective contraceptive measures up to 2 months after the end of study drug administration (females and males). Effective contraceptive measures include a hormonal birth control (e.g. oral pills, long term injections, vaginal ring, patch); the intrauterine device (IUD); a double barrier method (e.g. condom or diaphragm plus spermicide foam).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Georgia,   Germany,   Italy,   Serbia,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04899271
Other Study ID Numbers  ICMJE LDX0419
2020-002966-15 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Dompé Farmaceutici S.p.A
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Dompé Farmaceutici S.p.A
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Flavio Mantelli, MD Dompé Farmaceutici
PRS Account Dompé Farmaceutici S.p.A
Verification Date January 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP